Global Leader In Pharmaceutical Technology


IMD(INCREMENTALLY MODIFIED DRUG) PIPELINE PRODUCTS

PROJECT CODE INDICATION FORMULATION PRECLINICAL
STUDY
PHASE 1 PHASE 2 PHASE 3 FILED
GLA5PR NEUROPATHIC PAIN
GLH1SM DIABETES
GLH10PR NEUROPATHIC PAIN
GLK1SD DIABETES
GLF1MO ALLERGIC RHINITIS
GLF2LE PARKINSON DISEASE
GLF3AP ATOPIC DERMATITIS

NME(NEW MOLECULE ENTITY) PIPELINE PRODUCTS

PROJECT CODE INDICATION FORMULATION PRECLINICAL
STUDY
PHASE 1 PHASE 2 PHASE 3 FILED
GLH8NDE DRY EYE DISEASE

 GENERIC DRUG PIPELINE PRODUCTS

PROJECT CODE INDICATION FORMULATION PHASE 1 FILED
GL1901 PARKINSON DISEASE
GLI1AE HYPERLIPIDEMIA
CWI4TI POSTMENOPAUSAL
OSTEOPOROSIS
PMJ5DE BIRTH CONTROL
GLK2DM DIABETES
PMK3UL BIRTH CONTROL
PMF4TR MELASMA
PMK4DE BIRTH CONTROL(NEW DOSE)
PMK5GE BIRTH CONTROL(NEW DOSE)


전화 : 031-739-5220    |    팩스 : 031-739-5224

경기도 성남시 중원구 사기막골로 137 중앙인더스피아 5차 714호


GLPHARMTECH

Copyright 2014 ⓒ GLPharmTech. All Rights Reserved

mailmaster@glpt.co.kr